Our clinic is involved in several clinical trials. Participating in one of these studies is a very valuable contribution to the advancement of new treatments in MS.
Investigator initiated studies:
Industry sponsored studies:
Enrolling:
-
STRATIFY Observational Study: The MS Clinic at LSU Health Sciences Center in New Orleans is participating in a study for patients with Relapsing Remitting Multiple Sclerosis who are currently being treated with or considering treatment with Tysabri®. Study participants must be between 18 and 60 years of age. A blood sample will be collected from volunteers at the first visit and then once a year for two years for JC virus (JCV) antibody testing.
JCV is linked to progressive multifocal leukoencephalopathy (PML) and taking Tysabri® is associated with an increased risk of getting PML. The purpose of this study is to collect blood samples from people with Multiple Sclerosis (MS) who are taking Tysabri® or may take it as a treatment for MS to see if previous exposure to JCV may predict whether a person is at risk for developing PML while taking Tysabri®. Antibodies are produced by the body’s immune system when it detects foreign substances so prior exposure to JCV will be identified by presence of the antibody in the blood.
If you would like more information about this study, please e-mail Study Coordinator, Nicole Villemarette-Pittman at msclinic@lsuhsc.edu. Dr. Amy Gutierrez, Principal Investigator, and Dr. Jesus Lovera staff the MS Clinic at 2820 Napoleon Ave., Suite 700, New Orleans, LA, and will be happy to answer any questions that you may have about this clinical trial. The cost of the study laboratory test will be covered by the study sponsor, Biogen Idec. Participation involves 3 blood draws over 2 years and there is no compensation for volunteers.
Active, Fully Enrolled:
-
TYGRIS study: The purpose of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with multiple sclerosis (MS) treated with TYSABRI® (natalizumab).
Contact information:
If you are interested in participating in any of our studies please contact us at: msclinic@lsuhsc.edu or call us at 504-568-4092.
